New GIANTT publication on variability in response during RAAS inhibition

New GIANTT publication on variability in response during RAAS inhibition Thursday March 1st, 2018

Almost 2 million people in the Netherlands use renin-angiotensin aldosteron system blockers such as ACE inhibitors or ARBs. Yet, the effects of these drugs do widely vary between patients. Ellen Apperloo and colleagues used GIANTT data to investigate the interindividual response variability in 1600 people with diabetes type 2. They assessed differences in effects on blood pressure and albuminuria and related consequences for cardiovascular outcome. It was found that 51% were good responders on both blood pressure and albuminuria, 22% on blood pressure only, 17% on albuminuria only and 10% had poor response on both parameters. Important finding was that good responders had a significant lower risk for cardiovascular events compared to poor responders (Hazard ratio 0.51; 95%CI: 0.30-0.86, p=0.012). Read more here.

Share this

Contact us for more information